View Older Stories View More Recent Stories

Jul 12, 2021 05:14PM Form SC 13D Aerovate Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jul 12, 2021 04:31PM Form SC 13G Aerpio Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jul 9, 2021 04:32PM Form SC 13G GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.
Jul 7, 2021 03:30AM Adcendo Appoints Michael Pehl as Chief Executive Officer
Jun 30, 2021 04:34PM Form SC 13G Entera Bio Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 30, 2021 04:33PM Form SC 13D Therapeutics Acquisition Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 30, 2021 04:05PM POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
Jun 30, 2021 04:05PM POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
Jun 29, 2021 04:33PM Form SC 13G Cyteir Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 29, 2021 06:18AM Pardes Biosciences and FS Development Corp. II (FSII) Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company
Jun 29, 2021 06:00AM Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections
Jun 28, 2021 07:00AM POINT Biopharma Strengthens Senior Management Team with Appointment of Dr. Myra Rosario Herrle as EVP, Regulatory Affairs
Jun 28, 2021 07:00AM POINT Biopharma Strengthens Senior Management Team with Appointment of Dr. Myra Rosario Herrle as EVP, Regulatory Affairs
Jun 24, 2021 07:03PM Form 3 Therapeutics Acquisition For: Jun 23 Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 23, 2021 08:00AM Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer and Other Diseases
Jun 21, 2021 04:46PM Form SC 13G Novan, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 17, 2021 08:00AM LENZ Therapeutics Debuts With $47 Million Series A Financing
Jun 16, 2021 05:21PM Form SC 13D Janux Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 16, 2021 04:59PM Form SC 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 16, 2021 07:30AM DTx Pharma to Participate in the 2021 BMO BioPharma Day: Spotlight on Rare Disease and Ophthalmology
Jun 15, 2021 04:33PM Form SC 13G CATABASIS PHARMACEUTICAL Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 10, 2021 08:00AM Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform
Jun 9, 2021 10:05PM Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome
Jun 9, 2021 04:30PM Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT
Jun 9, 2021 08:00AM ViaCyte Announces Closing of $45 Million Financing to Advance Broadest Portfolio of Stem Cell-Derived Therapies for Type 1 Diabetes
Jun 7, 2021 05:13PM Form SC 13D/A Connect Biopharma Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 7, 2021 04:48PM Form SC 13G Day One Biopharmaceutica Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 7, 2021 09:00AM PepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments
Jun 7, 2021 07:30AM DTx Pharma Appoints Jill Howe as Chief Financial Officer
Jun 4, 2021 04:33PM Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 4, 2021 08:32AM POINT Biopharma Doses First Patients in Phase 3 Study of PNT2002 for mCRPC (RACA)
Jun 4, 2021 08:30AM POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
Jun 4, 2021 06:30AM POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
Jun 4, 2021 06:30AM POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
Jun 3, 2021 08:00AM AavantiBio and Resilience Announce Strategic Collaboration for Gene Therapy Development and Manufacturing
Jun 1, 2021 04:33PM POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility (RACA)
Jun 1, 2021 04:31PM POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
May 27, 2021 04:45PM Form SC 13G KalVista Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.
May 26, 2021 08:00AM NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
May 26, 2021 07:30AM DTx Pharma to Participate in Upcoming Virtual Investor Conferences
May 24, 2021 07:00AM Eliem Therapeutics Announces $60 Million Series B Financing
May 21, 2021 09:19AM Larimar Therapeutics (LRMR) Announces $95 Million Private Placement Financing of Common Stock, Warrants
May 21, 2021 09:18AM Larimar Therapeutics Announces $95 Million Private Placement Financing
May 18, 2021 12:01AM Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
May 17, 2021 04:45PM Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
May 17, 2021 04:44PM Form SC 13G/A FIVE PRIME THERAPEUTICS, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 17, 2021 04:41PM Form SC 13G/A Lyra Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 17, 2021 04:40PM Form SC 13G/A Pandion Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 17, 2021 04:37PM Form SC 13G/A Inhibrx, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 17, 2021 07:00AM AavantiBio Rounds Out Leadership Team with Appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer
View More Recent Stories View Older Stories